Theranostic treatment for prostate cancer involves targeting prostate specific membrane antigen (PSMA) on prostate cancer cells – first with a radioactive molecule to reveal the cancer’s spread via a PET (Positron Emission Tomography) scan and then a similar radioactive molecule that kills cancer cells. ProsTIC have pioneered research globally, performing our first PSMA PET scan in 2014, and our first PSMA therapy in 2015.
Prostate Theranostics and Imaging Centre of Excellence
Aims of the ProsTIC program
The program has three aims.
1. Accelerate clinical trial research
Expanding the portfolio of clinical trials investigating the use of PSMA PET imaging and therapy targeting areas of high impact need not currently being addressed.
2. Education and Leadership
Establishing a global hub of excellence to educate doctors, scientists, patients and the community about the application and benefits of this innovative technology.
3. Discovery research
Furthering investigate next generation targets, develop biomarkers to predict and monitor response to PSMA therapy, optimise new combinations with PSMA therapy in pre-clinical models, explore the use of radio-guided surgery and artificial intelligence image interpretation.
ProsTIC Contact
Email: